World Journal of Nuclear Medicine

CASE REPORT
Year
: 2014  |  Volume : 13  |  Issue : 2  |  Page : 142--143

Late Aminophylline Reversal of Regadenoson Stress Testing in Patients with End Stage Renal Disease


Muaz M Abudiab, Samuel Unzek Freiman 
 Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona, USA

Correspondence Address:
Dr. Muaz M Abudiab
13400 E. Shea Blvd., Scottsdale, AZ 85259
USA

Regadenoson is a widely used and well-tolerated vasodilator agent for pharmacologic stress myocardial perfusing imaging. In patients at higher risk of adverse reactions such as those with end stage renal disease, it can be reversed with early administration of aminophylline. However, little is known about late administration of aminophylline. This case report describes the efficacy of late aminophylline use in patients with end stage renal disease. Possible explanations for the prolonged pharmacodynamic effect of regadenoson in this group are discussed.


How to cite this article:
Abudiab MM, Freiman SU. Late Aminophylline Reversal of Regadenoson Stress Testing in Patients with End Stage Renal Disease.World J Nucl Med 2014;13:142-143


How to cite this URL:
Abudiab MM, Freiman SU. Late Aminophylline Reversal of Regadenoson Stress Testing in Patients with End Stage Renal Disease. World J Nucl Med [serial online] 2014 [cited 2022 Jan 21 ];13:142-143
Available from: http://www.wjnm.org/article.asp?issn=1450-1147;year=2014;volume=13;issue=2;spage=142;epage=143;aulast=Abudiab;type=0